Bicycle Therapeutics PLC expected to post a loss of 78 cents a share - Earnings Preview

Bicycle Therapeutics

29/10/2024 13:49

* Bicycle Therapeutics PLC  BCYC.OQ   BCYC.O  is expected
to show
a rise in quarterly revenue when it reports  results on October
31 (estimated) for the period ending September 30 2024
    * The Cambridge Cambridgeshire-based  company is expected to
report a 27.8% increase in revenue to $6.838 million from $5.35
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Bicycle Therapeutics PLC
is
for a loss of 78 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bicycle
Therapeutics PLC is 38.00​, above​ its last closing price
of $24.79. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -1.06       -1.10      -0.77     Beat    29.9
 Jan. 1 2024   -1.25                  -0.62             50.1
 Jan. 1 0001   -1.17       -1.23      -1.16     Beat    6​
 Sep. 30 2023  -1.16       -1.17      -1.26     Missed  -7.6
 ​​Jun.        -1.31       -1.29      -1.41     Missed  -9
 30 2023                                                
 Mar. 31 2023  -1.08       -1.07      -1.30     Missed  -21.1​
 Dec. 31 2022  -1.05       -1.06      -1.01     Beat    4.6
 Sep. 30 2022  -0.86       -0.89      -0.96     Missed  -8
 This summary was machine generated October 29 at 13:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)